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The membrane-type matrix metalloproteinases (MT-MMPs), an important subgroup of 
the wider MMP family, demonstrate widespread expression in multiple tumor types, and 
play key roles in cancer growth, migration, invasion and metastasis. Despite a large body 
of published research, relatively little information exists regarding evidence for MT-MMP 
expression and function in metastatic prostate cancer. This review provides an appraisal of 
the literature describing gene and protein expression in prostate cancer cells and clinical 
tissue, summarises the evidence for roles in prostate cancer progression, and examines 
the data relating to MT-MMP function in the development of bone metastases. Finally, the 
therapeutic potential of targeting MT-MMPs is considered. While MT-MMP inhibition 
presents a significant challenge, utilisation of MT-MMP expression and proteolytic capacity 
in prostate tumors is an attractive drug development opportunity. 
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INTRODUCTION
Several decades of research have established the 
matrix metalloproteinases (MMPs) as key players in 
the progression of cancer, largely through alterations 
observed in the tumor microenvironment. Indeed, 
MMPs have been considered as potential diagnostic 
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and prognostic biomarkers for many types and stages 
of cancer[1]. Despite their potential as therapeutic 
targets, however, a clinically useful agent has yet to 
materialise, despite several MMP inhibitors having 
been developed and evaluated in clinical trials[2]. More 
recently, attention has turned to the potential utility of 
MMPs as activators of targeted prodrug therapies[3-5]. 
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The MMP family of proteolytic enzymes comprises 
over  26 s t ruc tura l ly  s imi la r  z inc-dependent 
endoproteases. The wider family comprises two major 
subgroups: (1) the soluble or secreted MMPs and 
(2) the membrane-type MMPs (MT-MMPs). The MT-
MMPs are further sub-classified by their cell surface 
association, either by a transmembrane domain (as is 
the case for MT1-, MT2-, MT3-, and MT5-MMP) or by 
a glycophosphatidylinositol anchor (in MT4- and MT6-
MMP). The nomenclature for the MT-MMPs is outlined 
in Table 1: the gene and protein names are generally 
used interchangeably. The structures of the MT-MMP 
family have been well described[6]. They are each 
synthesised as inactive pre-pro enzymes in the Golgi 
apparatus, with cleavage of the signal peptide and pro-
domain required before transport to the cell surface.
The roles played by many MMPs in wider cancer 
initiation, progression and metastasis have been 
extensively explored, with pivotal roles described in 
prostate cancer in particular[7]. Expression and the 
roles played by the MT-MMP family in prostate cancer 
are less well studied, however, and it is this area that 
is the focus of this review. The available evidence 
for expression of MT-MMPs in prostate cancer cells 
and clinical tissues will be examined first, followed by 
consideration of their roles in prostate cancer function 
and in metastasis to the bone. 
EXPRESSION OF MT-MMPs IN PROSTATE 
CANCER CELL LINES
A significant body of literature exists concerning 
the expression of MT1-MMP in prostate cancer 
cell lines, albeit limited almost exclusively to the 
widely studied PC3, DU145 and LNCaP cell lines. 
Prostatic adenocarcinoma cells PC3 (derived from a 
bone metastasis) and DU145 (derived from a brain 
metastasis) are androgen-insensitive and metastatic 
(PC3 being the more aggressive of the two), while 
LNCaP cells (prostatic adenocarcinoma cells derived 
from a lymph node metastasis) are androgen-sensitive 
cells and non-metastatic[8].
MT1-MMP gene expression has been consistently 
reported in the androgen-insensitive, more metastatic 
cell lines PC3 (and sublines PC3-M and PC3-MM2[8]) 
and DU145. Expression has also been reported 
in TSU-Pr1 cells[9,10], also androgen-insensitive. 
Meanwhile, the less aggressive androgen-sensitive 
cell l ine LNCaP (and sublines LNCaP-C4 and 
LNCaP-C4-2[8]) exhibit low or an absence of MT1-
MMP gene expression[8,10-13]. Daja et al.[8] explain that 
despite these differences in gene expression, active 
MT1-MMP protein expression was identified in both 
LNCaP and PC3 cells and their sublines. Furthermore, 
Jennbacken et al.[14] demonstrated that transformation 
of LNCaP into an androgen-independent cell line 
(i.e. LNCaP-19[15]) was accompanied by increased 
aggressiveness (growth and migratory capacity) 
and by upregulation of both MT1-MMP gene and 
protein expression. The influence of the tumor 
microenvironment, specifically fibroblasts (WPF5), 
was investigated on PC3 and DU145 cells in a study 
by Coulson-Thomas et al.[16]. An increase in MT1-
MMP gene and protein expression was reported in co-
cultures of WPF5 and PC3 or DU145 cells. Protein 
was localised at the cellular projections of all cell 
lines. When considered together with changes in 
vimentin distribution and an up-regulation of integrin 
α5β1 expression, this is indicative of a more invasive 
phenotype.
Information regarding the remaining members of 
the MT-MMP family is more scarce. Interestingly, in 
contrast to the picture observed with MT1-MMP, MT2-
MMP gene expression has been reported as more 
significant in LNCaP cells and sublines than in PC3 
cells. The pattern of MT3-MMP gene expression is the 
opposite to this, and thus similar to that observed for 
MT1-MMP[8]. Protein levels were similar in both cell 
lines, however. Processed MT-MMPs, indicative of 
latent MMP activation, were observed to be increased 
in the more aggressive sublines. Jung et al. [11] 
described significant gene expression of MT2-
MMP and MT5-MMP in both cell types. MT3-MMP 
expression was observed in LNCaP cells with negligible 
expression in PC3 or DU145 cells. Meanwhile, MT4-
MMP expression was observed in PC3 and DU145, 
with negligible expression in LNCaP cells.
EXPRESSION OF MT-MMPs IN PROSTATE 
CANCER CLINICAL TISSUES
The clinical expression of secreted MMPs in prostate 
cancer has been well reviewed by Gong et al.[7], with 
expression of MMP-2, -3, -7, -9 and -13 gene and 
protein each identified in serum and tumor tissue of 
patients with prostate cancer, and correlation with 
progression and metastasis observed. Interestingly, 
Table 1: MT-MMP nomenclature
Gene Protein
MMP-14 MT1-MMP
MMP-15 MT2-MMP
MMP-16 MT3-MMP
MMP-17 MT4-MMP
MMP-24 MT5-MMP
MMP-25 MT6-MMP
MT-MMP: membrane-type matrix metalloproteinases
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MMP-1 expression has been associated with lower 
grade prostate tumors. In this section, we have 
summarised the clinical expression data available for 
MT-MMPs in prostate cancer tissues. 
Trudel et al.[17] examined tissues from 189 prostate 
cancer patients who had undergone surgery (radical 
prostatectomy). MT1-MMP expression and its 
effects on disease-free survival were examined 
immunohistochemically, differentiating cancer, stromal, 
and benign epithelial cells. This study showed that 
in 167 (88.8%) cases, MT1-MMP was expressed by 
benign epithelial cells and MT1-MMP was expressed 
by cancer cells in 171 (90.5%) cases. The expression 
in cancerous tissue was mostly observed in cells at 
or near the tumor front. Overall the expression was 
described as heterogeneous though cancer cells at the 
tumor margin were seen to always express MT1-MMP. 
The expression of MT1-MMP in benign epithelial cells 
was somewhat unexpected, given what is generally 
understood about MMPs in other cancers. The authors 
did raise the issue of the quality and specificity of 
commercial antibodies for MT1-MMP, and did further 
suggest that active MT1-MMP could be cleaved by 
other MMPs resulting in soluble fragments, which may 
have been detected. It is the potential effect of prostate 
cancer cells on the local microenvironment that is 
perhaps the key, however. The authors speculated 
as to whether the presence of MT1-MMP in benign 
epithelial cells (near cancerous tissue) from these 
patients might in fact be induced by the cancer. A study 
by Paterson et al.[18] in bladder cancer was cross-
referenced, which had further suggested that the so-
called “benign” epithelial cells in those patients were 
in fact not benign at all, but genotypically abnormal. 
These findings have been encountered by others and 
are worthy of further study. 
Discrepancies between gene expression (higher MT1-
MMP expression in benign prostate hyperplasia and 
prostate cancer tissues, when compared to normal 
prostate) and protein expression (lower expression in 
prostate cancer tissues compared to normal prostate 
and benign prostate hyperplasia) were noted by 
Neuhaus et al.[19]. These results contrast with most 
other published studies, which led the authors to 
speculate that cells of the prostate interstitium (included 
in assessment of total immunofluorescence due to 
MT1-MMP) may have increased protein expression 
and may account for the apparent levels of protein 
expression seen in epithelial cells.
Cardillo et al.[20] analysed 38 paraffin-embedded 
samples f rom prostate cancer pat ients (who 
h a d  u n d e r g o n e  r a d i c a l  p r o s t a t e c t o m y )  b y 
immunohistochemistry and compared prostate 
intraepithelial neoplasia (PIN) and its normal adjacent 
prostate (NAP) counterpart. MT1-MMP was observed 
to be more strongly expressed in tumor tissue than in 
PIN and NAP tissue, with the expression of MT1-MMP 
reaching its highest levels in the most aggressive 
prostate tumors with high Gleason scores (Gleason 
scores are used to grade prostate cancer, with a score 
above 7 indicative of aggressive, metastatic disease). 
Once again, expression was detected in surrounding 
stroma and epithelia, backing up the findings of 
Trudel et al.[17]. The authors speculate that stromal 
and tumor cells could co-operate in facilitating tumor 
cell invasion, hence the requirement for MT1-MMP 
expression, and that transition from benign epithelium 
via PIN to cancer is associated with changes in 
localisation of MT1-MMP in the prostate epithelium[20].
In a further 40 patients, Reis et al.[21] also monitored 
tissue inhibitor of matrix metalloproteinase 1 (TIMP-
1) expression together with that of MT1-MMP. TIMPs 
inhibit some MMPs and other protease enzymes, 
but not MT1-MMP[22]. The loss of TIMP-1 protein 
expression was correlated to cancer progression, 
with MT1-MMP protein expression being identified 
in the majority of prostate cancer specimens. Once 
again, a positive correlation with Gleason score 
was observed[21]. This reinforced an earlier study 
by the same group (79 prostate cancer patients), 
which indicated that MT1-MMP expression was 
higher in patient samples with Gleason scores ≥ 7, 
though that dataset only exhibited marginal statistical 
significance[23].
Upadhyay et al. [24] investigated the relationship 
between the MT1-MMP and MMP-2 expression, 
with immunohistochemistry confirmed by western 
blotting and gelatin zymography. A significant 
correlation between the pattern of MMP-2 and MT1-
MMP expression within the epithelial components 
of individual specimens was observed. Differential 
staining was seen between benign epithelia, high-
grade PIN, and prostate cancer. In benign glands, 
the greatest expression for MT1-MMP was in basal 
cells (BCs), whereas secretory cells were rarely 
positive. Conversely in high-grade PIN, secretory cells 
showed consistent cytoplasmic staining. In cancer 
cells, staining was heterogeneous and varied from no 
staining to very intense staining in select glands[24].
High expression of insulin-like growth factor-1 
receptor (IGF-1R) in prostate cancer was identified 
by Sroka et al.[25], who suggested that using MT1-
MMP localization and IGF-1R expression may serve 
as a predictive biomarker of aggressive disease. MT1-
MMP expression was high in the apical regions of the 
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luminal cells in PIN and prostate cancer cells, though 
less intense in the basolateral regions of benign 
tissues. IGF-1R was expressed primarily in the basal 
cells of normal glands and highly expressed in prostate 
cancer tissues[25]. 
As is the case with studies on cell lines, the majority of 
clinical reports focus on expression of MT1-MMP. Both 
Jung et al.[11] and Riddick et al.[26] compared a wider 
range of MT-MMP family member gene expression 
in paired tissue samples from non-malignant and 
malignant parts of the same prostate cancer patient 
biopsies, using real-time polymerase chain reaction 
(PCR). Interestingly, Jung et al. [11] identified a 
significant down-regulation for all investigated MT-
MMPs except for MT2-MMP in malignant tissue 
and did not detect a correlation between tumor 
classification and MT-MMP expression. Riddick et al.[26] 
investigated MT-MMP gene expression in 44 prostate 
cancer cases and 23 benign prostate hyperplasia 
specimens, also by real-time PCR. This study 
additionally found increased gene expression of MT2-
MMP, MT5-MMP and MT6-MMP in malignant tissue 
compared to benign prostate tissue, and suggested 
that these proteases are likely to participate directly 
in prostate tumor invasion. It is important to note that 
MT6-MMP was primarily expressed by the epithelial 
cancer cells rather than stromal cells. The lack of 
difference in MT1-MMP expression between malignant 
and local non-malignant tissue perhaps provides 
further evidence for the conclusions previously 
discussed[17,18,20].
The evidence for MT-MMP expression, and particularly 
MT1-MMP expression, in prostate cancer cells and 
tumors from patients is compelling. The picture 
is complicated by the involvement of the tumor 
microenvironment, in which MT-MMP expression is 
influenced, perhaps initiated, by the development of 
cancer. In the following section, the roles of individual 
MMPs are considered, along with links to other 
pathways known to be important in prostate cancer 
progression and metastasis.
FUNCTIONS OF MT-MMPs IN PROSTATE 
CANCER PROGRESSION AND METASTASIS
It is widely accepted that MT-MMPs play key roles 
in the metastatic process[27]. With regards prostate 
cancer, MT-MMPs have been identified as contributing 
towards apoptosis, angiogenesis, proliferation and 
metastasis[7]. MT-MMPs have been shown to be 
involved in various molecular processes in prostate 
cancer progression and metastasis, which will now be 
considered here, together with information regarding 
potential regulatory pathways. Some of the molecular 
events associated with MT-MMP expression and 
function in tumor cell migration, angiogenesis and 
vascular signalling are summarised in Figure 1[28].
MT1-MMP plays a role in epithelial-to-mesenchymal 
transition (EMT). EMT is an important process in the 
metastatic cascade, involving multiple oncogenic 
drivers[29]. Cao et al.[30] initially used DNA microarray 
database mining to reveal upregulation of MT1-MMP 
in human primary and metastatic prostate cancer 
samples. Using 3D cell culture models, the study 
additionally demonstrated that transformation of 
LNCaP cells with MT1-MMP induced morphological 
changes  and  modu la t i on  o f  ep i t he l i a l  and 
mesenchymal markers consistent with EMT, and 
thus metastatic transformation. Further experiments 
demonstrated that  these MT1-MMP-induced 
phenotypic changes were linked to Wnt5a, also 
associated with EMT[31]. These findings are supported 
by the aforementioned study by Jennbacken et al.[14], 
which similarly described E-cadherin downregulation 
and N-cadherin upregulation (both consistent with 
EMT) in the androgen-independent LNCaP-19 cell 
line, accompanied by increased MT1-MMP. 
Degradation of the extracellular matrix (ECM), and 
specifically laminin-10 (Ln-10), was explored by 
Bair et al.[32]. Laminins are key glycoprotein components 
of the ECM: providing structural support to the basal 
lamina in both normal prostate and malignant tissue. 
The authors point to evidence previously published 
describing upregulation of Ln-10 as prostate cancer 
progresses from normal to PIN through to invasive 
cancer, suggesting a role for MT1-MMP in the invasion 
of prostate cancer[33]. Here, recombinant MT1-MMP 
(and MT1-MMP-expressing cells and tissues) was 
shown to cleave the α5 chain of purified human Ln-
10 from its 350-kDa form into specific fragments. 
This cleavage was shown to decrease cell adhesion 
to purified Ln-10, and to increase transmigration of 
DU-145 cells through cleaved Ln-10 and thus the 
basal lamina. Increased invasion mediated by MT1-
MMP was also observed by Wang et al.[34]. Using 
cells engineered to overexpress MT1-MMP (namely 
PC3-LN4), invasion into type-I collagen gels in vitro 
was observed, through activation of pro-MMP2. PC3-
LN4 cells additionally proliferated at a faster rate 
than mock-transfected control cells when grown 
subcutaneously in nude mice.
Endo180 (uPARAP, urokinase-type plasminogen 
activator receptor-associated protein) regulates 
collagen remodelling and chemotactic cell migration 
through cooperat ion with MT1-MMP. A study 
by Kogianni et al. [35] describes how Endo180 is 
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positively correlated with prostate cancer clinical 
risk and suggests that it is a stronger predictor of 
Gleason score than serum PSA. Endo180 disrupts 
epithelial cell contact and plays a potential role in 
EMT in prostate cancer. Endo180 and MT1-MMP co-
expression was identified as strongly upregulated 
in the stroma of prostate cancer with low clinical 
r isk, indicating that tumor-associated stromal 
fibroblasts can acquire the ability for effective collagen 
degradation and internalisation at the early stages of 
tumor development. These findings are interesting 
and add further support to prostate cancer cells 
influencing MT1-MMP expression in their surrounding 
microenvironment.
The transcription factor p53 is known to play significant 
roles as a tumor suppressor in cancer progression. 
Wang et al.[36] considered the involvement of p53 in 
prostate cancer cell invasion and metastasis, using 
DU145 cells in which p53 was silenced by siRNA. 
Increased invasion and metastasis were observed in 
a series of in vitro experiments, including increased 
MT1-MMP expression and activity, along with that 
of MMP-2 and MMP-9. These findings are also 
consistent with the studies associating MT1-MMP 
with EMT, as demonstrated by reduced E-cadherin, 
increased N-cadherin and enhanced vimentin staining. 
The authors additionally provide evidence that these 
effects are mediated via FAK-Src signalling. 
A study by Sankpal et al.[37] provides evidence for 
regulation of MT1-MMP by specificity protein 1 (Sp1). 
Sp1 is expressed in a number of different cancers, and 
plays key regulatory roles in processes associated 
with prostate cancer progression and metastasis. 
DU-145 cells were reported to express constitutively 
phosphorylated ERK, while PC3 and PC3N cells 
express constitutively phosphorylated AKT/PKB and 
c-Jun NH2 terminal kinase (JNK). Interestingly, both 
MT1-MMP and Sp1 levels were decreased in PC3 cells 
when PI3K and JNK were inhibited, and MT1-MMP 
levels were decreased in DU-145 cells when MEK 
was inhibited. These results suggest Sp1-mediated 
transcriptional regulation of MT1-MMP in prostate 
cancer cell lines via differential signalling control[13,37]. 
Sroka et al.[25] additionally considered the relationship 
between IGF-1R and MT1-MMP in prostate cancer 
cells and tissues, the expression data for which were 
discussed earlier. IGF-1R has been identified to play a 
role in prostate cancer metastatic progression, through 
PI3K, MAP kinase and ERK signalling[38]. Interestingly, 
decreased MT1-MMP expression at mRNA and 
Figure 1: Membrane type-MMPs regulate cell signalling in cancer. MT1-MMP regulates cell migration through both ECM proteolysis and non-proteolytic-
dependent TIMP-2 activation of ERK1/2 pathway. MT1-MMP regulates VEGF gene expression through Src, Akt, and mTOR activation and stimulates tumor 
angiogenesis. Roles for MT-MMP expression are also associated with TGFβ, Tie-2 and PDGFRβ. Figure was originally published by Sounni et al.[28]. MT-MMP: 
membrane-type matrix metalloproteinases; ECM: extracellular matrix; VEGF: vascular endothelial growth factor
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protein level resulted from inhibition of IGF-1R (using 
picropodophyllin) in PC3N cells. Increased IGF-1R, 
when activated by IGF-1, led to increased MT1-MMP 
expression and activity following treatment of LNCaP 
cells with synthetic androgen R1881.
Reversion-inducing cysteine-rich protein with 
Kazal motifs (RECK), originally found to suppress 
transformation caused by the oncogene KRAS, 
is a glycoprotein tumor suppressor which inhibits 
metastasis and angiogenesis[39]. Previous studies 
have identified RECK as an inhibitor of various MMPs, 
including MT1-MMP[40]. Rabien et al.[41] identified 
RECK expression in prostate cancer cell lines and 
tissue and observeda significant decrease in malignant 
tissue. Significantly, RECK overexpression led to 
a dramatic reduction in tumor cell invasion and a 
decrease of pro-/active MT1-MMP expression (up to 
53% of control).  
Filiz and Dass[42] demonstrated decreased expression 
of MT1-MMP associated with reduced pigment 
epithelium-derived factor (PEDF).The authors 
noted that PEDF had been previously found to be 
downregulated in prostate cancer patients (specifically 
in high-grade PIN, the most likely precursor of 
prostate cancer)[43]. PEDF was examined for effects 
on PC3 cells, with increased adhesion to ECM 
protein collagen-I and decreased expression of 
phosphorylated FAK observed. Tumor cell invasion 
through collagen-I was also reduced. These findings 
were attributed to the decreased expression of MT1-
MMP.
Increased expression of both MT1-MMP and LIM 
kinase 1 (LIMK1) in prostate tumor tissues was 
reported by Tapia et al.[44]. LIMK1 is a downstream 
effector of Rho signalling, modulates actin dynamics 
and is overexpressed in prostate cancer cells, 
where it promotes invasion and metastasis. Results 
showed that treatment with ilomastat (broad-spectrum 
hydroxamate-based MMP inhibitor) reduced LIMK1-
induced invasion of benign prostate epithelial cells 
(BPH-1 cells) suggesting that the process is mediated 
by MMPs, notably MT1-MMP. Increased MT1-MMP 
expression in cells overexpressing LIMK1 was also 
reported, along with transcriptional activation and 
localisation of protein to the plasma membrane. LIMK1 
was shown to physically associate with MT1-MMP and 
to co-localise with it in Golgi vesicles, thereby enabling 
transport of MT1-MMP to the cell surface[44].
FGFR4 expression and polymorphism has been linked 
to prostate cancer progression and drug resistance[45]. 
In particular, a single nucleotide polymorphism (SNP) 
in codon 388 of the human FGFR4 gene has been 
linked to poor prognosis in prostate cancer patients. 
This SNP results in Gly388 being transformed to Arg 
in the transmembrane domain of the receptor, leading 
to prolonged FGFR4 receptor activation[46]. MT1-
MMP and FGFR4 were found to be co-expressed in 
the tumor edges and prostate carcinoma: MT1-MMP 
upregulation was observed in cancer cells (9 of 14) 
and/or reactive stroma (9 of 14), whereas FGFR4 
expression was mainly found in the tumor cells. 
FGFR4-R388 was shown to enhance MT1-MMP-
mediated prostate cancer cell invasion. FGFR4 was 
thus also identified as playing a role in MT1-MMP-
dependent ECM degradation and tumor progression 
involving EMT in vivo[47].
MT1-MMP has additionally been associated with 
oxidative stress in prostate cancer cell lines. Nguyen et al.[48] 
described how expression of MT1-MMP increased 
oxidative DNA damage via reactive oxygen species 
(ROS) in LNCaP and in DU145 cells, causing oxidative 
stress. The study confirmed the findings of others in 
demonstrating that MT1-MMP is associated with a 
more aggressive phenotype as illustrated by increased 
cell migration, invasion and anchorage-independent 
cell growth. Use of the scavenger N-acetylcysteine to 
block ROS activity inhibited the MT1-MMP-mediated 
increase in cell migration and invasion. The authors 
additionally suggested a role for β1-integrins in 
facilitating cell adhesion to matrix proteins, and that 
this was necessary for induction of ROS in MT1-MMP-
expressing prostate cancer cells.
PTEN (phosphatase and tensin homologue deleted 
on chromosome ten) is a phosphatase enzyme 
involved in regulation of PI3K-Akt pathway signalling 
and thus cancer progression. Most metastatic 
prostate cancers exhibit loss-of-function mutations or 
deletions of this key tumor suppressor[49]. Kim et al.[50] 
considered the role of PTEN inactivation on MT-MMP 
expression in prostate cancer. Mouse PTEN null 
cells exhibited up-regulation of MT1-MMP and MT3-
MMP gene expression (and the associated increased 
migration and invasion), and increased MT1-MMP 
protein expression in vivo. Interestingly, the MT1-MMP 
displayed by PTEN null cells exhibited a slow rate of 
turnover, which was thought to be due to differential 
O-glycosylation of the MT1-MMP hinge region 
modulating enzyme stability. MT1-MMP expression 
in PTEN null cells was additionally determined to be 
regulated by PI3K/Akt but not MAPK signalling, as 
determined by inhibitors of those pathways. A role for 
downstream pathway mTORC1 (positively regulates 
translation thereby promoting protein synthesis[51]) was 
predicted, given the upregulation of MT-MMP protein 
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expression, but intriguingly inhibition by rapamycin 
(an mTOR inhibitor) actually upregulated MT1-MMP 
protein expression in PTEN null cells further, an 
effect that was reversed by Akt inhibition. The authors 
discuss this potential side effect of rapamycin, and 
note that similar observations have been reported 
elsewhere[50].
As was the case with expression data, information 
regarding the roles of the other members of the MT-
MMP family is somewhat limited. Delassus et al.[12] 
identified a series of prostate cancer progression 
modulators and engineered overexpression in 
prostate cancer cells (PC3) and others. Changes in 
gene expression of MT1-, MT3- and MT6-MMP were 
then evaluated. Over-expression of activator protein-
2α, interleukin 4 and p16INK4α had no effect on MT-
MMP expression. Fibulin1D led to down-regulation 
of MT1- and MT3-MMP (no reliable data for MT6-
MMP). Supporting the work of Wang et al.[36], p53 over-
expression led to reduced MT1-MMP expression (no 
reliable data for the other MT-MMPs evaluated). Over-
expression of PTEN produced no change in MT1-
MMP expression, which is at odds with the data of 
Kim et al.[50], with the caveat that cells in that study 
were mouse prostate cancer cells. Upregulation of 
MT3-MMP was observed, however. Furthermore, 
raf kinase inhibitor protein over-expression led to 
increased MT1-MMP, with no change detected for 
the others. Finally, over-expression of E-cadherin led 
to reduced expression of all three MT-MMPs. This 
finding thus reinforces the observations discussed 
earlier regarding the role of MT-MMPs in EMT (i.e. a 
phenotypic shift from E- to N-cadherin expression)[14,30,36].
Lin et al.[52] undertook genomic association studies 
to identify genetic variants, i.e. SNPs utilising data 
from the Cancer Genetic Markers of Susceptibility 
dataset, which includes data from 1,151 prostate 
cancer patients. The authors explain how SNP-SNP 
interactions, rather than studying individual SNPs, 
potentially have greater impact on unravelling the 
underlying mechanisms of complex disease[52]. Three 
important SNP-SNP interactions were identified, linking 
MT3-MMP to ROBO1, CSF-1 and EGFR. ROBO1 
is a member of the roundabout immunoglobulin 
superfamily, and has been identified as playing key 
roles in prostate cancer progression[53]. It is cleaved 
by MMPs and translocates into the nucleus of cancer 
cells, which perhaps suggests a signalling role. The 
authors suggest that as no specific MMP has to-date 
been linked to ROBO1 cleavage, these data may have 
uncovered the potential for such a role for MT3-MMP. 
Colony stimulating factor-1  has been associated with 
increased tumor angiogenesis[52]. Epidermal growth 
factor receptor (EGFR) plays an important role in 
regulating cancer cell growth and function, not least 
in prostate cancer, and is therapeutically important[54]. 
More recently, a much wider study by the same group 
using the prostate cancer PRACTICAL consortium 
data with approximately 21,000 patients, identified four 
key SNP-SNP interactions found to be associated with 
prostate cancer aggressiveness. Of relevance here, 
this study again linked MT3-MMP and EGFR[55]. 
In addition, several studies point to an important role 
for MT-MMPs, and MT1-MMP in particular, in the 
processes associated with metastatic spread to bone 
in prostate cancer. This data will be considered in the 
following section.
EXPRESSION AND ROLES OF MT-MMPs IN 
PROSTATE CANCER BONE METASTASIS
It is suggested that more than 80% of patients with 
disseminated prostate cancer will present with 
metastasis to the bone[56,57]. Skeletal complications 
are thus one of the leading causes of morbidity and 
mortality in prostate cancer patients. The normal 
equilibrium between osteoblastic and osteolytic 
activity in bone is disturbed in prostate cancer, leading 
to changes that are likely to provide a favourable 
microenvironment for metastatic colonisation. Given 
the established roles for MMPs in normal bone 
remodelling, a role for MMPs in prostate cancer 
bone metastasis has long been proposed[58]. With 
this in mind, it is perhaps surprising that relatively 
little research has been directed to the MT-MMPs in 
this area to-date. MT1-MMP knock-out mice exhibit 
severe skeletal abnormalities, confirming a role in 
normal bone maintenance and development[59]. Given 
these roles in normal bone health, the expression of 
MT-MMPs in prostate cancer cells and tissues led 
Bonfil et al.[58] to speculate as to the existence of a 
selective process in which prostate cancer cells may 
have a greater propensity to metastasise to bone, or 
whether the microenvironment within the bone itself 
may induce MMP expression in prostate cancer cells, 
after their arrival at the bone.
Nemeth et al.[60] evaluated MT-MMP expression 
in clinical samples and the role of MMP activity in 
prostate cancer that had metastasised to the bone, 
using a preclinical mouse model of bone metastasis 
employing PC3 xenografts. MT1-MMP protein 
expression (as identified by immunohistochemical 
staining) was consistently observed in the 18 core 
bone biopsy samples from prostate cancer patients. In 
preclinical studies, single human foetal bone fragments 
were implanted subcutaneously in immunodeficient 
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mice. After an interval of 4 weeks, PC3 cells were then 
injected directly into some of the implants, with/without 
initiation of daily treatment with broad-spectrum MMP 
inhibitor batimastat for 2 weeks. MT1-MMP expression 
was subsequently identified in PC3 bone tumors, 
localised primarily to tumor cells, with some stromal 
expression noted. The PC3 bone tumors were mostly 
osteolytic in nature, and MMP inhibition by batimastat 
reduced the number of osteoclasts per millimetre in 
these implants. The authors concluded that MT1-MMP 
activity in prostate cancer cells appears to be crucial 
in bone matrix turnover. This, together with metastatic 
tumor growth, appeared to be linked in cycle that is 
disrupted by MMP inhibition[60].
A further correlation between MT1-MMP expression in 
prostate cancer cells and bone metastasis was also 
reported by Bonfil et al.[61]. MT1-MMP expression was 
abundant and consistent in tumor cells identified in 
paraffin sections of bone metastases from 20 prostate 
cancer patients (androgen independent disease). 
It should be noted that MT1-MMP expression was 
noted in endothelial cells, osteocytes, osteoblasts and 
stroma in matched normal bone samples, consistent 
with a role in bone development, albeit at expression 
levels which appear significantly lower than those 
exhibited by the tumor cells. Preclinical models were 
utilised to examine the role of MT1-MMP in metastatic 
bone colonisation of prostate cancer cells. MT1-
MMP was introduced into LNCaP cells, while it was 
silenced (using siRNA for MT1-MMP) in DU145 cells. 
MT1-MMP over-expression enhanced bone tumor 
growth (via intra-tibial injection) and associated 
osteolysis, while not affecting cell proliferation in vitro 
or subcutaneous tumor growth in vivo. This led the 
authors to conclude that MT1-MMP contributes a 
unique stimulatory effect on tumor growth in the bone 
microenvironment. Further studies utilising orthotopic 
models which better replicate the normal disease 
dissemination process are required to confirm these 
findings, but the authors nevertheless suggest the 
possibility that MT1-MMP activity may be worthy of 
pursuing as a therapeutic target for prostate cancer 
bone metastases. Furthermore, a role for RANKL 
was suggested: RANKL (receptor activator of NF-
κB ligand) is a regulator of osteoclastogenesis, and 
its release in the bone microenvironment was linked 
to MT1-MMP activity. siRNA knockdown of MT1-
MMP inhibited bone tumor growth of DU145 cells and 
simultaneously led to osteogenesis, a phenomenon 
for which mechanistic information was not obtained. 
It was suggested that MT1-MMP inhibition may have 
shifted the balance toward bone formation simply by 
inhibition of osteolysis/osteoclastogenesis[61].
Sabbota et al.[62] subsequently followed up their initial 
findings and provided further evidence for a link 
between RANKL shedding and MT1-MMP protein 
expression, summarised in Figure 2. In this study, 
conditioned media from LNCaP cells expressing both 
RANKL and MT1-MMP was shown to enhance cell 
migration of LNCaP-C4-2b cells, which are MT1-MMP 
deficient. This was inhibited by osteoprotegerin (soluble 
decoy receptor of RANKL) and selective MT1-MMP 
inhibitor MIK-G2. The authors hypothesised that these 
findings indicated that MT1-MMP enhances tumor 
cell migration through initiation of an autocrine loop 
requiring RANKL shedding in prostate cancer cells. 
Evidence was also provided for a role for Src as a 
downstream mediator of RANKL[62]. 
The importance of cadherin-11 in prostate cancer 
bone metastasis was considered by Huang et al.[63]. 
Cadherin-11 is an osteoblast cadherin, identified as 
being aberrantly expressed in prostate cancer cells 
derived from bone metastases[64]. LNCaP-C4-2B4 cells 
in which expression of cadherin-11 had been engineered 
demonstrated increased spread and intercalation into 
an osteoblast layer in vitro and exhibited enhanced 
migration and invasion. Downregulation of cadherin-11 
in PC3 cells, which naturally express cadherin-11, 
decreased cell migration and invasion. A possible role 
for MT2-MMP was suggested, following gene array 
analysis of the LNCaP-C4-2B4 cells. Several genes 
related to invasion and metastasis were identified as 
upregulated, among which MT2-MMP was a prominent 
finding[63]. Interestingly, IGF-1 gene expression was also 
reported as upregulated, which supports the evidence 
provided by Sroka et al.[25] relating to a role for IGF-
1R in MT-MMP expression and activity, as discussed 
earlier.
MT-MMPs clearly play important roles in the 
development of metastatic bone deposits. Given 
that most patients with prostate cancer ultimately 
succumb to metastasis, a strategy to specifically target 
MT1-MMP-expression on tumor cells may prove an 
attractive means by which to address prostate cancer 
metastasis to bone.
OPPORTUNITIES FOR DRUG TARGETING 
The expression of MT-MMPs in prostate cancer 
and associated bone metastases suggests an 
opportunity for targeted therapy. As an example, the 
Bonfil group focused on MT1-MMP expression in 
prostate cancer bone metastases, and suggested 
that the increased MT1-MMP activity was worthy of 
pursuing as a therapeutic strategy. The group later 
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went on to propose a combination of Src inhibition 
with RANKL and/or selective MT1-MMP inhibition as 
a strategy, particularly for prostate cancer patients 
with bone metastases. Other strategies are worthy of 
investigation, utilising the knowledge that has been 
gained in understanding key pathways and how 
they interact with MT1-MMP activity, as have been 
discussed. Further study is required to fully understand 
the expression and roles of MT-MMPs in normal cells 
in the tumor microenvironment, however, given the 
possibility that tumor cells may induce expression in 
benign epithelial cells. Furthermore, very few studies 
contain data from healthy individuals for true “normal” 
tissue comparison.
MMP inhibit ion is an area that has been well 
explored in the past by big pharma, but has yet to 
fulfil its clinical potential. This is due to the complex 
roles of individual MMPs and their inter-connected 
compensatory mechanisms, poor clinical trial design, 
and drugs lacking exquisite selectivity[2,65]. Utilising 
MMP expression and proteolytic activity, however, 
is perhaps a more attractive approach[5,66]. This is 
especially true given the role of MMPs in angiogenesis 
and in maintenance of tumor vasculature[67,68]. While 
not specifically studied in prostate cancer, evidence 
for other cancers is compelling, particularly for MT1-
MMP[66,67].
The need for novel therapeutics in metastatic 
prostate cancer is clear. The burden of drug toxicity 
endured by many patients, often elderly and frail, 
means that an emphasis must be placed on targeted 
agents with minimal side effects. Small molecule 
chemotherapeutics remain central to prostate cancer 
therapy, but despite some considerable recent 
advances, these new agents still suffer from a lack 
of selectivity and dose-limiting toxicities. There is 
therefore considerable interest in the development of 
prodrugs to tailor the pharmacokinetics of molecules 
in favour of tumor-selective drug targeting, thereby 
decreasing these dose-limiting side effects and 
enhancing therapeutic index[69]. Multiple reviews have 
been published covering a huge range of approaches 
for cancer drug delivery, but it is fair to say that 
Figure 2: Diagram representing the most representative roles of MT1-MMP at bone metastatic sites. MT1-MMP expression by cancer cells results in proteolytic 
cleavage of tumor-associated membrane-bound RANKL (mRANKL), generating a soluble form of RANKL (sRANKL) that activates RANK favouring migration 
of tumor cells and osteoclastogenesis, respectively. Roles for MMP-7, MMP-9 and MMP-13 were also described. Reprinted by permission from Macmillan 
Publishers Ltd.[78]. MT-MMP: membrane-type matrix metalloproteinases
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prodrug approaches specifically developed for prostate 
cancer are limited. MMP-activated prodrugs in prostate 
cancer are considered by Barve et al.[70]. Here the 
concept of attaching an MMP-recognition peptide 
to a drug is discussed. Peptide conjugation renders 
the drug inactive (thereby creating the prodrug) until 
such time that tumor-expressed MMPs recognise and 
cleave the peptide to release the drug. This area has 
considerable potential. Further examples are provided 
by Choi et al.[3] and Law and Tung[4].
ICT-2588 is a prodrug of azademethylcolchicine 
(an analogue of colchicine[71]) and is a potent anti-
vascular agent [Figure 3]. Activated by MT1-MMP, 
ICT-2588 has shown promise in preclinical studies, 
successfully achieving enhanced therapeutic index[72], 
an absence of cardiotoxicity[73], and activity in a range 
of tumor types, not least prostate cancer (activity in 
PC3 xenografts in mouse models)[73]. This potential 
for the treatment of prostate tumors led the authors 
to apply the same technology to paclitaxel, yielding 
ICT-3205 [74]. This agent provides for enhanced 
tumor delivery of paclitaxel in preclinical studies 
(PC3 xenograft in mice), realising 10-fold increases 
in tumor concentrations (as measured by in vivo 
pharmacokinetics studies) while decreasing the 
exposure of drug to normal tissues, and associated 
toxicities. Given the findings of the STAMPEDE 
prostate cancer trial supporting earlier use of taxanes 
in treatment of metastatic prostate cancer[75-77], this 
approach is particularly timely.
While our understanding of the roles of MT-MMPs in 
prostate cancer and metastatic disease is growing all 
the time, much is still to be learnt. The potential for 
exploiting the proteolytic capacity of these enzymes is 
without question, but it remains to be seen whether a 
clinically useful drug molecule will emerge.
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